INTRODUCTION

“If we had a pill that contained all the benefits of exercise, it would be the most widely prescribed drug in the world,” stated Ronald M. Davis, former president of the American Medical Association. Recent efforts to search for an exercise pill has increased. An exercise pill contains bioactive compounds that mimic the beneficial effects of exercise without exercising. Major efforts have focused on approaches to understand the molecular mechanisms underlying fatty acid oxidation, mitochondrial biogenesis, and oxidative fiber-type transformation induced by activation of peroxisome proliferator-activated receptor gamma coactivator-1α to determine whether compounds such as AICAR, GW1516, and resveratrol mimic the health effects of aerobic exercise. According to a systematic review by Katakami et al., ursolic acid (UA) showed the same beneficial effects of aerobic and resistance exercises on sarcopenia and obesity.

UA is a pentacyclic triterpenoid present in many plants such as rosemary, basil fruit, apple, and coffee. It has a range of biological activities. In regard to muscle mass, UA has beneficial effects similar to those of resistance exercise. UA improves insulin/insulin-like growth factor-I (IGF-1) signaling, reduces atrophy by decreasing the expression of muscle RING-finger protein-1 (MuRF1) and muscle atrophy F-box (MAFbx), and induces muscle hypertrophy. The effects of UA treatment when used alone have not been demonstrated in an animal model of atrophy with hindlimb immobilization (IM), but UA in combination with other treatments such as low-intensity treadmill exercise is effective in increasing skeletal muscle mass. If UA shows beneficial effects similar to those exhibited by resistance exercise, it can be proposed as an exercise pill for the prevention of osteoporosis because resistance exercise is one of the best methods to strengthen bones. Beginning with a study reporting that UA increases bone-forming activity, several studies report that UA inhibits osteoclast production and bone loss. However, no research has been conducted on the potential effects of UA as a resistance exercise mimetic that simulta-
Exercise mimetic effects of ursolic acid.

In this study, the effects of dietary UA on muscle mass and bone microstructure were investigated using a Sprague-Dawley (SD) rat model of atrophy. The aim of this study was to demonstrate the potential of UA as a resistance exercise mimic.

METHODS

This study used 18 8-week-old male Sprague-Dawley (SD) rats (Central Lab. Animal Inc., Seoul, Korea). Following an adaptation period of 1 week in a laboratory setting with constant temperature (21°C) and humidity (40–60%), IM was performed on the left hindlimb of SD rats to induce muscle atrophy and the right hindlimb was used as an internal control (IC). After a 10 day IM period, six rats were euthanized and examined for IM-induced atrophy and the corresponding levels of bone mineral density (BMD). SD rats were divided into two groups after immobilization, SED (sedentary, n=6) and UA (n=6) groups, and treated with UA for the following 8 weeks. Body weight was measured using an electronic balance (Navigator N0B110; Ohaus Co., NJ, USA) once a week between 9 and 10 am before UA injection, and the skeletal muscles and bones were extracted from the euthanized rats after 8 weeks of treatment for analysis. Rats were euthanized by cervical dislocation under anesthesia. All rats were allowed free access to food (carbohydrate 58.9%, fat 12.4%, protein 28.7%; Purina corp. MO, USA) and water without restrictions.

Casting-induced muscle atrophy and UA injection

Rats were anesthetized with pentobarbital sodium (50 mg/kg of body mass; Fort Dodge Animal Health, USA) and immobilized using plaster casts. Rats had plaster casts on the left hindlimb only and the right hindlimb was reserved for use as IC, thus no treatment was given. During the IM period, rats were monitored daily for clinical conditions of the hindlimb such as edema and discoloration, and SD rats with such issues were excluded from the experiment.

UA treatment was carried out as per the same method used in a previous study. UA was dissolved in distilled water containing 0.1% Tween 80 (Sigma, USA) and administered by intraperitoneal injection (5 mg/kg) once per day (Liu et al., 2013). The SED group received the same dose of vehicle (distilled water containing 0.1% Tween 80) by intraperitoneal injection.

Tissue collection and muscle mass

Tissue collection was performed under anesthesia using pentobarbital sodium (50 mg/kg of body mass; Fort Dodge Animal Health, USA). Skeletal muscles such as gastrocnemius (GAS), soleus (SOL), tibialis anterior (TA), and extensor digitorum longus (EDL) were extracted and weighed using an electronic balance (EPG213, Ohaus Co., USA). The weight measurements were used to calculate the recovery rate for the IC.

RESULTS

Changes in muscle mass and BMD during the 10-day IM

The effects of IM-induced hindlimb muscle atrophy on BMD were examined to evaluate the beneficial effects of UA treatment on muscle mass and the deleterious effect on bones caused by IM (Fig 1). Ten days of hindlimb IM resulted in decreased muscle mass for GAS (41%), SOL (45%), TA (30%), and EDL (29%) muscles (p<0.05). BMD was reduced by 49% (p<0.05).

Bone microstructure

After skeletal muscles were collected, the hip joint area was cut and fixed in 10% paraformaldehyde, followed by micro-CT (SkyScan 1076 system; Bruker microCT, Kontich, Belgium) imaging taken for bone microstructure assessment.

For the cancellous bone of proximal tibia, CT Analyzer software (Bruker microCT, Kontich) was used to analyze the BMD, trabecular bone volume fraction (BV/TV), trabecular number (Tb.N), and trabecular separation (Tb.Sp) within the region of interest (ROI) of the proximal growth plate. Three-dimensional (3D) images were generated using CT Vol Realistic Visualization software (Bruker microCT, Kontich).

5. Statistical analysis

Data are presented as mean ± standard error of the mean (SEM) using SPSS 12.0 (SPSS Inc., Chicago, Illinois, USA). An unpaired t-test was conducted to compare skeletal muscle mass during the 10-day IM, and a one-way ANOVA was carried out to evaluate the improvements in skeletal muscle mass after 8 weeks of UA treatment. In addition, two-way ANOVA was used to determine the bone-related effects of 8-week UA treatment between the treatment conditions (SED and UA) and internal control (IC) or immobilization (IM). A Bonferroni post hoc test was performed, and the significance level was p<0.05.
Effects of UA atrophic skeletal muscle and the deleterious effect on bones

Fig 2 shows the recovery rate of muscle mass for the UA group, with the SED group mean set at 100%. The 8-week UA treatment showed a recovery rate varying from 4.5% to 11.3% depending on muscle type. However, a significant increase ($p<0.05$) was only observed in the GAS muscle.

Fig 3 summarizes the changes in BMD and bone microstructure observed by micro-CT. In the SED group, BMD, BV/TV, Tb.N, and Tb.Sp showed negative results ($p>0.05$) due to IM, but no statistical difference was observed between IC and IM concerning the 8-week UA treatment (Fig. 3B). These results were also observed in 3D images (Fig 3A). However, there was no statistically significant difference between the SED and UA groups regarding IM for all categories.

**DISCUSSION**

The aim of this study was to demonstrate the beneficial effects of UA on muscle mass and bone microstructure, rather than explore concrete UA mechanisms for alleviating the deleterious effects of skeletal muscle atrophy on the bone.

Skeletal muscle-bone interaction involves crosstalk. Therefore, resistance exercise for building muscle can be a highly effective treatment to preserve and increase BMD and bone strength. However, due to the high risk of musculoskeletal injury, resistance exercise has limited applications, especially in the elderly with less physical strength. The discovery of a substance that mimics the effect of resistance exercise, allowing users to achieve the positive effects of high-intensity resistance exercise with low-intensity exercise, will benefit many individuals who require resistance exercise, such as the one designed to alleviate the deleterious effect of muscle atrophy on the bone.

UA reduces atrophy by inhibiting the expression of hypertrophy- and atrophy-related genes MuRF1 and MAFbx, and increasing the activity of the insulin/IGF-1 signaling pathway. Recent studies show that UA prevents retinoic acid-induced bone loss and ameliorates the deleterious effect on bones in streptozotocin-induced diabetic mice. Such beneficial effects of UA involve bone formation induced by the regulated expression of osteoblast-specific genes, such as mitogen-activated protein kinases, nuclear factor NF-κB, and activator protein-1. These effects are based on enhanced osteogenesis caused by NF-κB signaling, tryptophan hydroxylase, and suppressed osteoclast differentiation. These effects of UA indicate potential as a bioactive compound that mimics the beneficial effects of resistance exercise on the bone. However, these discoveries alone are insufficient for UA to be accepted as a resistance exercise mimetic. This study offers key findings in support of the suggestion that UA has potential as a resistance exercise mimetic. First, the effects of 8 weeks of UA treatment on atrophic skeletal muscles induced by hindlimb IM (Fig 1) were examined and an increase in GAS muscle...
Exercise mimetic effects of ursolic acid.

ACKNOWLEDGMENTS

This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea (NRF-2016S1A5A8019355).

REFERENCES

1. Handschin C. Caloric restriction and exercise “mimetics”: Ready for prime time? Pharmacol Res. 2016;103:158-66.
2. Craig DM, Ashcroft SP, Belew MY, Stocks B, Currell K, Baar K, Philip A. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. Front Physiol. 2015;6:296.
3. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H, Shaw RJ, Evans RM. AMPK and PPARα agonists are exercise mimetics. Cell. 2008;134:405-15.
4. Li S, Laher I. Exercise pills: at the starting line. Trends Pharmacol Sci. 2015;36:907-16.
5. Katashima CK, Silva VR, Gomes TL, Pichard C, Pimentel GD. Ursolic acid and mechanisms of actions on adipose and muscle tissue: a systematic review. Obes Rev. 2017;18:700-11.
6. Ullevig SL, Zhao Q, Zamora D, Asmis R. Ursolic acid protects diabetic mice against monocye dysfunction and accelerated atherosclerosis. Atherosclerosis. 2011;219:409-16.
7. Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, Alipour F, Shields RK, Adams CM. Identification and small molecule inhibition of an activating transcription factor 4 (ATF4)-dependent pathway to age-related skeletal muscle weakness and atrophy. J Biol Chem. 2015;290:25497-511.
8. Bang HS, Seo DY, Chung YM, Oh KM, Park JJ, Arturo F, Jeong SH, Kim N, Han J. Ursolic Acid-induced elevation of serum irisin augments muscle strength during resistance training in men. Korean J Physiol Pharmacol. 2014;18:441-6.
9. Jeong JW, Shim JJ, Choi ID, Kim SH, Ra J, Ku HK, Lee DE, Kim TY, Jeung W, Lee JH, Lee KW, Huh CS, Sim JH, Ahn YT. Apple pomace extract improves endurance in exercise performance by increasing strength and weight of skeletal muscle. J Med Food. 2015;18:1389-96.
10. Kim JC, Kang YS, Noh EB, Seo BW, Seo DY, Park GD, Kim SH. Concurrent treatment with ursolic acid and low-intensity treadmill exercise improves muscle atrophy and related outcomes in rats. Korean J Physiol Pharmacol. 2018;22:427-36.
11. Hong AR, Kim SW. Effects of resistance exercise on bone health. Endocrinol Metab (Seoul). 2018;33:435-44.
12. Lee SU, Park SJ, Kwak HB, Oh J, Min YK, Kim SH. Anabolic activity of ursolic acid in bone: Stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo. Pharmacol Res. 2008;58:290-6.
13. Tan H, Furuta S, Nagata T, Ohnuki K, Akasaka T, Shirouchi B, Sato M, Kondo R, Shimizu K. Inhibitory effects of the leaves of loquat (Eriobotrya japonica) on bone mineral density loss in ovariecitized mice and osteoclast differentiation. J Agric Food Chem. 2014;62:836-41.
14. Jiang C, Xiao F, Gu X, Zhai Z, Liu X, Wang T, Wang Y, Zhu Z, Dai K, Qiu A, Wang J. Inhibitory effects of ursolic acid on osteoclastogenesis and titanium particle-induced osteolysis are mediated primarily via suppression of NF-κB signaling. Biochimie. 2015;111:107-18.
15. Cheng M, Liang XH, Wang QW, Deng YT, Zhao ZX, Liu XY. Ursolic acid prevents retinoic acid-induced bone loss in rats. Chin J Integr Med. 2019;25:210-5.
16. Yu SG, Zhang C, Xu XE, Sun JH, Zhang L, Yu PF. Ursolic acid derivative ameliorates streptozotocin-induced diabetic bone deleterious effects in mice. Int J Clin Exp Pathol. 2015;8:3681-90.
17. Coutinho EL, Gomes AR, Franca CN, Salvini TF. A new model for the immobilization of the rat hind limb. Braz J Med Biol Res. 2002;35:1329-32.
18. Colaianni G, Mongelli T, Colucci S, Cinti S, Grano M. Cross talk between muscle and bone via the muscle-myokine irisin. Curr Osteoporos Rep. 2016;14:132-7.
19. Gorski JP, Price JL. Bone muscle crosstalk targets muscle regeneration pathway regulated by core circadian transcriptional repressors DEC1 and DEC2. Bonekey Rep. 2016;5:850.
20. Maurel DB, Jähn K, Lara-Castillo N. Muscle–Bone Crosstalk: Emerging Opportunities for Novel Therapeutic Approaches to Treat Musculoskeletal Pathologies. Biomedicines. 2017;5:662.
21. Ogasawara R, Fujita S, Homburger TA, Kitacka Y, Makanea Y, Nakazato K, Nakata K. The role of mTOR signalling in the regulation of skeletal muscle mass in a rodent model of resistance exercise. Sci Rep. 2016;6:31142.
PR, Michelin MA, Chica JE, Murta EF, Orsatti FL. Acute resistance exercise reduces increased gene expression in muscle atrophy of ovariectomised arthritic rats. Prz Menopauzalny. 2016;15:193-201.

24. Faigenbaum AD, Kraemer WJ, Blimkie CJ, Jeffreys I, Micheli LJ, Nitka M, Rowland TW. Youth resistance training: updated position statement paper from the national strength and conditioning association. J Strength Cond Res. 2009;23:S60-79.

25. Fu HJ, Zhou YR, Bao BH, Jia MX, Zhao Y, Zhang L, Li JX, He HL, Zhou XM. Tryptophan hydroxylase 1 (Tph-1)-targeted bone anabolic agents for osteoporosis. J Med Chem. 2014;57:4692-709.